Bleeding

Neurology·MeSH: Hemorrhage

19 drugs in development·14 companies·3 clinical trials

Drug Pipeline by Phase

Approved(10)

Drug	Company
andexxa	PORTOLA PHARMACEUTICALS INC (PTLA)
diclofenac	Zomedica Corp. (ZOMDF)
HELIOGEN Fibrillar Collagen Matrix	MiMedx Group Inc (MDXG)
ixinity	XOMA Royalty Corporation (XOMA)
Jada	Organon & Co. (OGN)
promacta	Novartis AG (NVS)
promacta kit	Novartis AG (NVS)
sodium nitroprusside	NEXUS BIOPHARMA INC (NEXS)
tranexamic acid	ANI PHARMACEUTICALS INC (ANIP)
vetigel	Zomedica Corp. (ZOMDF)

Phase 3(6)

Drug	Company
Albumin	Crinetics Pharmaceuticals, Inc. (CRNX)
bentracimab	PhaseBio Pharmaceuticals Inc (PHAS)
nonacog beta pegol	Novo Nordisk A/S (NVO)
recombinant factor xiii	Novo Nordisk A/S (NVO)
turoctocog alfa	Novo Nordisk A/S (NVO)
turoctocog alfa pegol	Novo Nordisk A/S (NVO)

Unknown(1)

Drug	Company
tachosil	SIGA TECHNOLOGIES INC (SIGA)

Phase 4(2)

Drug	Company
Albumin	ENANTA PHARMACEUTICALS INC (ENTA)
genotyping guided therapy for anti-platelet management	GH Research PLC (GHRS)

BioSniper tracks 19 drugs in development for Bleeding across 14 companies.

There are 3 clinical trials targeting Bleeding tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.